Baseline Libraries demographic characteristics demonstrated similar prognostic features in both arms. The results of the IMPACT trial

demonstrated an overall survival benefit with a 22% reduction in the risk of death, and a 4.1 month median survival benefit. These results are consistent with the results of prior Phase 3 trials (Table 1), which demonstrated a 33% reduction in risk of death and a 4.3 month median survival benefit. This survival prolongation is clinically meaningful in a patient population with a median survival of less than 2 years [6] and [7]. A positive treatment effect was observed in a large SB431542 number of subgroups, including those defined by age, race, ECOG performance status, number of bone metastases, and previous chemotherapy use [10]. The time to objective disease progression did not differ significantly between the two treatment groups in these Phase 3 studies [6] and [7]. Adverse events associated with sipuleucel-T were generally infusion-related and self-limited. An integrated safety analysis of 4 randomized, Doxorubicin in vivo double-blind, controlled Phase 3 trials (D9901, D9902A, IMPACT, and a randomized trial in androgen dependent prostate cancer patients; n = 601 sipuleucel-T; n = 303 control) demonstrated that

the adverse events that were more commonly observed with sipuleucel-T (at a rate at least twice that of control) were: chills (53.1%), pyrexia (31.3%), headache (18.1%), myalgia (11.8%), influenza-like illness (9.7%), and hyperhidrosis (5.0%) [11]. These events generally occurred within 1 day of infusion, were mild or moderate in severity, and resolved within 2 days. There was no evidence of an increased incidence of autoimmune events or secondary malignancies. The incidence of reported serious adverse events was 24.0% for sipuleucel-T

very and 25.1% for control subjects. Grade ≥3 adverse events were reported within 1 day of infusion for 6.7% of sipuleucel-T and 2.3% of control subjects. The cerebrovascular event incidence rate reported was 3.5% for sipuleucel-T subjects and 2.6% for control subjects, and there was no evidence of a difference in the time to onset of cerebrovascular events (293 days [range: 2–1328] vs. 301.5 days [range: 7–707] for sipuleucel-T vs. control, respectively), or in the incidence of non-neurologic arterial (1.0% vs. 0.7%; sipuleucel-T vs. control) or venous (2.8% vs. 4.0%) vascular events [11]. Product characterization from the IMPACT trial demonstrated that APC activation (assessed via CD54 upregulation [12]) was evident in all products, and the magnitude of activation was greater in the second and third products; APC activation was not observed in the control product [13]. The magnitude of cumulative CD54 up-regulation in these 3 trials correlated with overall survival [14].